UA
45
-3
PDCO
33
-2
CME
45
-3
ALLE
64
2
DD
42
2
CFG
48
2
LEG
20
-2
CTSH
65
4
SWKS
42
4
KMX
50
-2
TGT
48
4
THC
49
2
SCHW
48
6
AMAT
57
3
HOG
45
11
AMZN
52
2
LH
38
5
CSCO
61
3
EFX
44
-3
IBM
77
3
UA
45
-3
PDCO
33
-2
CME
45
-3
ALLE
64
2
DD
42
2
CFG
48
2
LEG
20
-2
CTSH
65
4
SWKS
42
4
KMX
50
-2
TGT
48
4
THC
49
2
SCHW
48
6
AMAT
57
3
HOG
45
11
AMZN
52
2
LH
38
5
CSCO
61
3
EFX
44
-3
IBM
77
3
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

Forget Bitcoin - This Is the Real Opportunity of 2024

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30

HALO
Halozyme Therapeutics

Last Price:
50.66
Seasonality Move:
20.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Urgent: The Biggest Gold Bull Market in History Is Here

Click here for urgent details - don't miss out.

Halozyme Therapeutics Price Quote

$50.66
+0.01 (+-6.41%)
(Updated: October 10, 2024 at 6:26 AM ET)

Halozyme Therapeutics Key Stats

Sell
30
Halozyme Therapeutics (HALO) is a Sell
Day range:
$49.63 - $54.41
52-week range:
$32.83 - $65.53
Dividend yield:
0%
P/E ratio:
25.78
P/S ratio:
8.11
P/B ratio:
23.69%
Volume:
3.2M
Avg. volume:
1.5M
1-year change:
36.74%
Market cap:
$6.9B
Revenue:
$829.3M
EPS:
$2.58

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.05%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.29%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $420M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$236.8M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$216.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 19.96%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 18.24%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 177.29%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 28.57% 20.1%
Revenue: 4.67% 12.89%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.00
Upside from Last Price: 22.41%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    194M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders